Assessment of platelet activation indices using the ADVIATM120 amongst ‘high‐risk’ patients with hypertension
- 1 January 2007
- journal article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 39 (1), 72-78
- https://doi.org/10.1080/07853890601040063
Abstract
Platelet activation is involved in the pathogenesis of the thrombotic complications of hypertension. Novel surrogate markers of platelet activation (mean platelet volume (MPV), mean platelet component (MPC, measure of platelet density), platelet component distribution width (PCDW, a marker of platelet shape change) and the number of platelet clumps) have been related to cardiovascular risk. We hypothesized a stepwise increase in these platelet activation indices between healthy controls (HC, n = 60), 'high-risk' essential hypertensive subjects (HBP, n = 45) and treated, previously diagnosed patients with malignant phase hypertension (MHT, n = 45). In a cross-sectional study, we measured comparative platelet counts and indices of platelet activation (MPV, MPC, PCDW and the number of platelet clumps) using the Bayer ADVIATM haematology system, in our three study groups. There was a stepwise increase in MPV (P = 0.0002) and MPM (P = 0.03), and a stepwise decrease in the MPC (P = 0.03) and PCDW (P = 0.001) across the three study groups, despite similarities in platelet count. These differences were only significantly different (on post-hoc analysis) between the healthy controls and the MHT group. On multivariate analysis, there was a significant relationship (R2 = 66.5%; P<0.0001) between the MPV and the PCDW (P<0.0001), systolic blood pressure (P = 0.008) and platelet count (P<0.0001). There is a stepwise increase in platelet activation indices, despite similar platelet counts, with increasing severity of hypertensive disease. This may contribute to the pathogenesis of thrombosis-related complications in hypertension.Keywords
This publication has 27 references indexed in Scilit:
- The mean platelet volume in patients with essential and white coat hypertensionPlatelets, 2005
- Mean platelet volume in patients with type 2 diabetes mellitusPlatelets, 2004
- Platelet indexes in relation to target organ damage in high-risk hypertensive patients: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Journal of the American College of Cardiology, 2004
- Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapyAnnals of Medicine, 2004
- Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic strokeThrombosis and Haemostasis, 2004
- Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplastyThrombosis and Haemostasis, 2004
- The Prothrombotic State in Hypertension and the Effects of Antihypertensive TreatmentCurrent Pharmaceutical Design, 2003
- Hypertension, Platelets, and the EndotheliumHypertension, 2003
- A reliable plasma marker of platelet activation: Does it exist?American Journal of Hematology, 2002
- Flow Cytometric Detection of Activated Platelets: Comparison of Determining Shape Change, Fibrinogen Binding, and P-Selectin ExpressionSeminars in Thrombosis and Hemostasis, 1995